Suppr
超能文献

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions.

作者信息

Khor Yet H, Farooqi Malik, Hambly Nathan, Kolb Martin, Ryerson Christopher J

机构信息

Monash University Melbourne, Victoria, Australia.

Austin Health Heidelberg, Victoria, Australia.

出版信息

Am J Respir Crit Care Med. 2023 Jan 1;207(1):102-105. doi: 10.1164/rccm.202205-0910LE.

DOI:10.1164/rccm.202205-0910LE

PMID:35943331

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9952865/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7249/9952865/13559e339ebe/rccm.202205-0910LEf1.jpg

相似文献

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions.

Am J Respir Crit Care Med. 2023 Jan 1;207(1):102-105. doi: 10.1164/rccm.202205-0910LE.

Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK.

Adv Ther. 2018 May;35(5):724-736. doi: 10.1007/s12325-018-0693-1. Epub 2018 Apr 11.

Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.

Lancet Respir Med. 2015 Jun;3(6):462-72. doi: 10.1016/S2213-2600(15)00048-X. Epub 2015 Mar 12.

The clinical impact of major comorbidities on idiopathic pulmonary fibrosis.

Respir Investig. 2017 Mar;55(2):94-103. doi: 10.1016/j.resinv.2016.11.004. Epub 2017 Jan 14.

From pulmonary fibrosis to progressive pulmonary fibrosis: a lethal pathobiological jump.

Am J Physiol Lung Cell Mol Physiol. 2021 Sep 1;321(3):L600-L607. doi: 10.1152/ajplung.00310.2021. Epub 2021 Jul 28.

Further characterization of computed tomographic and clinical features for staging and prognosis of idiopathic pulmonary fibrosis in West Highland white terriers.

Vet Radiol Ultrasound. 2017 Jul;58(4):381-388. doi: 10.1111/vru.12491. Epub 2017 Mar 23.

Definitions of disease: should possible and probable idiopathic pulmonary fibrosis be enrolled in treatment trials?

Respir Investig. 2015 May;53(3):88-92. doi: 10.1016/j.resinv.2014.12.005. Epub 2015 Mar 4.

Diabetes Mellitus Contributes to Idiopathic Pulmonary Fibrosis: A Review From Clinical Appearance to Possible Pathogenesis.

Front Public Health. 2020 Jun 3;8:196. doi: 10.3389/fpubh.2020.00196. eCollection 2020.

Idiopathic pulmonary fibrosis: an Australian perspective.

Intern Med J. 2016 Jun;46(6):663-8. doi: 10.1111/imj.13078.

Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.

Respir Med. 2013 Feb;107(2):249-55. doi: 10.1016/j.rmed.2012.10.018. Epub 2012 Nov 24.

引用本文的文献

Initiation of antifibrotic treatment in fibrosing interstitial lung disease: is the clock ticking till proven progression?

Eur Respir Rev. 2025 Aug 6;34(177). doi: 10.1183/16000617.0023-2025. Print 2025 Jun.

Validation of the gender, age, physiology model and other prognostic factors in interstitial lung disease patients with systemic autoimmune rheumatic disease.

Sci Rep. 2025 Jul 9;15(1):24691. doi: 10.1038/s41598-025-08484-3.

Epidemiology and Prognosis of Progressive Pulmonary Fibrosis: A Literature Review.

Pulm Ther. 2025 Jun 16. doi: 10.1007/s41030-025-00302-5.

Progressive Pulmonary Fibrosis: Current Status in Terminology and Future Directions.

Adv Ther. 2025 May 19. doi: 10.1007/s12325-025-03215-6.

Analysis of treatment efficacy, tolerability, and survival of patients receiving antifibrotic therapy for progressive nonidiopathic pulmonary fibrosis.

Ann Thorac Med. 2025 Apr-Jun;20(2):98-107. doi: 10.4103/atm.atm_213_24. Epub 2025 Mar 31.

Comorbidities in the idiopathic pulmonary fibrosis and progressive pulmonary fibrosis trial population: a systematic review and meta-analysis.

Eur Respir Rev. 2025 Mar 19;34(175). doi: 10.1183/16000617.0238-2024. Print 2025 Jan.

Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON.

Lung. 2025 Jan 9;203(1):25. doi: 10.1007/s00408-024-00778-z.

Exercise-Induced Oxygen Desaturation and Outcomes After Nintedanib Therapy for Fibrosing Interstitial Lung Disease in Patients Without Dyspnea.

J Clin Med. 2024 Dec 23;13(24):7865. doi: 10.3390/jcm13247865.

Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis.

Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666241309795. doi: 10.1177/17534666241309795.

Acute exacerbations in patients with progressive pulmonary fibrosis.

ERJ Open Res. 2024 Dec 2;10(6). doi: 10.1183/23120541.00403-2024. eCollection 2024 Nov.

本文引用的文献

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.

Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.

Eur Respir J. 2022 Oct 6;60(4). doi: 10.1183/13993003.02571-2021. Print 2022 Oct.

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.

Lancet Respir Med. 2021 May;9(5):476-486. doi: 10.1016/S2213-2600(20)30554-3. Epub 2021 Mar 30.

Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review.

Eur Respir Rev. 2020 Aug 4;29(157). doi: 10.1183/16000617.0158-2019. Print 2020 Sep 30.

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.

Lancet Respir Med. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. Epub 2019 Sep 29.

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29.

The Canadian Registry for Pulmonary Fibrosis: Design and Rationale of a National Pulmonary Fibrosis Registry.

Can Respir J. 2016;2016:3562923. doi: 10.1155/2016/3562923. Epub 2016 Apr 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Patient Characteristics and Survival for Progressive Pulmonary Fibrosis Using Different Definitions.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译